Clinical Trials Logo

Prediabetic State clinical trials

View clinical trials related to Prediabetic State.

Filter by:

NCT ID: NCT05346978 Completed - Pre Diabetes Clinical Trials

Nasturtium (Tropaeolum Majus L) Intake and Biochemical Parameters in Pre-diabetic Subjects in Bogota Colombia

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

Brassicaceae plant family have a high content of bioactive compounds such as e.g. glucosinolates (GSLs) and isothiocyanates (ICTs) associated, recently, with diabetes prevention. This research proposal has the intention of evaluating if the ingestion of freeze-dried nasturtium has a positive effect on the insulin response, lipid profile, oxidative stress biomarkers and gene expression of RESISTIN, GLUT 4, acetyl-CoA carboxylase-a (ACC), fatty acid synthase (FASN), NRF-2, NQO1, SFRXN1, glutathione peroxidase 2 (GPx-2), FOXO1, FOXO3 and FOXO6 in subjects with glucose intolerance.

NCT ID: NCT05344196 Completed - PreDiabetes Clinical Trials

Emotional Awareness and Expression Therapy for Prediabetes

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

This feasibility study seeks to develop and pilot test Emotional Awareness and Expression Therapy as a possible treatment for people with prediabetes.

NCT ID: NCT05329610 Completed - Prediabetes Clinical Trials

β-alanine Supplementation in Adults With Overweight/Obesity

BASA-O
Start date: April 5, 2022
Phase: N/A
Study type: Interventional

The study will investigate the safety, feasibility, and efficacy of beta-alanine supplementation in adults with overweight or obesity. Beta-alanine is a widely used dietary supplement that can increase the amount of carnosine in skeletal muscle. Both carnosine and beta-alanine occur naturally in animal food products and previous research shows that supplementation with beta-alanine leads to an improvement in exercise performance; more recently, the present investigators have shown that increasing carnosine can also help to improve cardiometabolic health, detoxify skeletal muscle, and improve glucose (sugar) uptake into muscle cells. The investigators will recruit 30 participants (15 per arm) with overweight or obesity who meet the study criteria (this accounts for up to 20% attrition - a minimum of 12 participants per arm). Those who are eligible will be required to receive three short telephone calls and attend three laboratory sessions. Participants will be randomised to receive either beta-alanine or placebo (an inactive sugar pill) for the 3-month study period. To see whether beta-alanine supplementation is feasible in this population the investigators will measure recruitment, adherence (how well people can stick to the supplement regime), the number and nature of side effects, and blinding to the intervention. Markers of cardiac function, glycaemic control, and metabolic health will also be explored. All measurements will take place before and after a 3-month supplementation period. This will provide us with novel information of the role of beta-alanine and carnosine in cardiometabolic health; and will aid in the planning of a larger randomised controlled trial to assess the efficacy of beta-alanine supplementation as a therapeutic strategy.

NCT ID: NCT05290506 Completed - Type 2 Diabetes Clinical Trials

Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus

Start date: August 1, 2020
Phase: Phase 3
Study type: Interventional

There are studies that suggest glycemic response to incretin-based therapies differs between Asians and Caucasians, whereby Asians have better response compared to Caucasians. Hence, the therapeutic response could also be augmented by difference in incretin system among various ethnicities. This study is carried out to study the effect of dipeptidyl-peptidase IV (DPPIV) inhibitors in prediabetes and T2DM patients who have different levels of GLP-1 and to determine the effect on glycemic profiles, insulin resistance/sensitivity, beta-cell functon.

NCT ID: NCT05238012 Completed - Clinical trials for Metabolism Disorder, Glucose

Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes

XTREME
Start date: August 2, 2022
Phase: Phase 4
Study type: Interventional

This study is a prospective, randomized, open-label, multi-center trial. The primary objective of the study is to assess whether XZK 1200mg/d, compared to atorvastatin 20mg/d, has a favorable impact on HbA1c levels at 24 weeks of treatment in dyslipidemia patients with prediabetes

NCT ID: NCT05208424 Completed - Clinical trials for Coronary Artery Disease

New Diabetes Mellitus and Pre-Diabetes With First-time Diagnosed Coronary Artery Disease

DMCAD
Start date: February 27, 2020
Phase:
Study type: Observational [Patient Registry]

A prospective analytic study to evaluate the incidence, clinical and laboratory characteristics, extent of coronary artery disease and short-term outcome of newly diagnosed diabetes and pre-diabetes in patients with first-time diagnosed coronary artery disease treated in Saud Al Babtain Cardiac Center.

NCT ID: NCT05166512 Completed - Pre-diabetes Clinical Trials

Pilot Trial of a Novel Cooking Skills Intervention (DPPCooks) to Prevent Diabetes

DPPCooks
Start date: February 2, 2022
Phase: N/A
Study type: Interventional

In this pilot trial participants will be randomized 1:1 to participate in either standard Diabetes Prevention Program (DPP) vs. DPP plus a novel cooking skills intervention (DPP Cooks). The researchers hypothesize that participants randomized to DPP Cooks will have greater weight loss, better diet quality at 4 months, and greater confidence in their cooking skills and ability to implement dietary changes recommended in the DPP.

NCT ID: NCT05114018 Completed - Metabolic Syndrome Clinical Trials

Effect of Pasteurized Akkermansia Muciniphila on Insulin Resistance in Otherwise Healthy Subjects With Dysglycaemia

Start date: June 24, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the efficacy of pasteurized Akkermansia muciniphila (pAKK) in improving insulin sensitivity in hyperglycaemic, but otherwise healthy persons with metabolic syndrome. This is the primary objective of this study. Secondary objectives consist of evaluation of the effects of next generation beneficial microbes on metabolic health, anthropometry and body composition, and safety. Therefore, the trial is designed as a phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center trial comparing pAKK with placebo in restoring insulin sensitivity in dysglycaemic but otherwise healthy subjects with metabolic syndrome. In total, 144 enrolled participants will attend 6 study visits in total. Study visits may be conducted in the clinic, at home by a Healthcare Professional, or by telephone / telemedicine.

NCT ID: NCT05112146 Completed - Prediabetic State Clinical Trials

Effects of Whey Protein Pre-meals on Post-prandial Glucose

Start date: August 20, 2018
Phase: N/A
Study type: Interventional

The aim of this project was to determine if an administration of either 10 g of whey protein isolate or 10 g of whey protein microgels 30 or 10 min before a standard meal could reduce postprandial glucose response in obese subjects.

NCT ID: NCT05102851 Completed - Clinical trials for Diabetic Cardiomyopathy

Impact of Prediabetes on Acute Coronary Syndrome

Start date: August 1, 2021
Phase:
Study type: Observational [Patient Registry]

Diabetes mellitus is one of the chronic non-communicable diseases which have emerged as a leading global health problem. According to the International Diabetes Federation Atlas guideline report, currently, there are 352 million adults with impaired glucose tolerance who are at high risk of developing diabetes in the future. In 2017, it was estimated that 425 million people (20-79 years of age) suffered from Diabetes mellitus, and the number is expected to rise to 629 million by 2045. Moreover, Egypt is considered one of the top 10 countries in the world